Legend Biotech (NASDAQ: LEGN) has recently received a number of price target changes and ratings updates:
- 11/14/2026 – Legend Biotech was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/13/2026 – Legend Biotech was downgraded by Evercore from “outperform” to “in-line”. They now have a $20.00 price target on the stock.
- 11/11/2026 – Legend Biotech had its price target lowered by Morgan Stanley from $49.00 to $43.00. They now have an “overweight” rating on the stock.
- 11/11/2026 – Legend Biotech had its price target lowered by Oppenheimer from $40.00 to $25.00. They now have a “market perform” rating on the stock.
- 11/11/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $56.00 to $50.00. They now have an “outperform” rating on the stock.
- 11/11/2026 – Legend Biotech had its price target lowered by Barclays from $68.00 to $61.00. They now have an “overweight” rating on the stock.
- 11/9/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 10/30/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright.
- 10/19/2026 – Legend Biotech was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 10/13/2026 – Legend Biotech had its price target lowered by Barclays from $74.00 to $68.00. They now have an “overweight” rating on the stock.
- 10/9/2026 – Legend Biotech had its price target lowered by JPMorgan Chase & Co. from $35.00 to $33.00. They now have a “neutral” rating on the stock.
- 10/8/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $58.00 to $56.00. They now have an “outperform” rating on the stock.
- 10/2/2026 – Legend Biotech was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 9/28/2026 – Legend Biotech had its “buy” rating reaffirmed by UBS Group. They now have a $65.00 price target on the stock.
- 9/28/2026 – Legend Biotech had its “buy” rating reaffirmed by HC Wainwright. They now have a $65.00 price target on the stock.
Legend Biotech Trading Down 0.9%
LEGN traded down $0.15 during trading hours on Thursday, hitting $16.10. The company’s stock had a trading volume of 2,367,653 shares, compared to its average volume of 2,435,184. The company has a 50-day simple moving average of $19.30 and a 200 day simple moving average of $22.10. The firm has a market capitalization of $3.12 billion, a PE ratio of -1,608.39 and a beta of 0.55. Legend Biotech Corporation Sponsored ADR has a fifty-two week low of $15.73 and a fifty-two week high of $37.50.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. The company had revenue of $359.50 million during the quarter, compared to analyst estimates of $361.46 million. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.05) EPS. Research analysts expect that Legend Biotech Corporation Sponsored ADR will post -0.02 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total value of $258,920.20. Following the completion of the transaction, the director owned 52,731 shares in the company, valued at $498,835.26. This represents a 34.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Carlos Santos sold 5,430 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the transaction, the chief financial officer owned 14,246 shares of the company’s stock, valued at $130,208.44. This represents a 27.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.02% of the company’s stock.
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Read More
- Five stocks we like better than Legend Biotech
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Legend Biotech Corporation Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech Corporation Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
